PHARMANIAGA BHD
KLSE (MYR): PHARMA (7081)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
0.355
Today's Change
-0.005 (1.39%)
Day's Change
0.355 - 0.365
Trading Volume
697,200
Financial
Market Cap
Market Cap
512 Million
NOSH
1,441 Million
Latest Quarter
Latest Quarter
30-Sep-2024 [#3]
Announcement Date
26-Nov-2024
Next Quarter
31-Dec-2024
Est. Ann. Date
28-Feb-2025
Est. Ann. Due Date
01-Mar-2025
QoQ | YoY
3,512.16% | 304.77%
T4Q Result
Revenue | NP to SH
3,622,844.000 | 96,754.000
RPS | P/RPS
251.37 Cent | 0.14
EPS | P/E | EY
6.71 Cent | 5.29 | 18.91%
DPS | DY | Payout %
0.00 Cent | 0.00% | 0.00%
NAPS | P/NAPS
-0.12 | 0.00
QoQ | YoY
280.45% | 114.04%
NP Margin | ROE
2.74% | 0.00%
F.Y. | Ann. Date
30-Sep-2024 | 26-Nov-2024
Latest Audited Result
Latest Audited Result
31-Dec-2023
Announcement Date
29-Apr-2024
Next Audited Result
31-Dec-2024
Est. Ann. Date
29-Apr-2025
Est. Ann. Due Date
29-Jun-2025
Annual (Unaudited)
Revenue | NP to SH
3,404,481.000 | -77,452.000
RPS | P/RPS
236.22 Cent | 0.15
EPS | P/E | EY
-5.37 Cent | -6.61 | -15.14%
DPS | DY | Payout %
0.00 Cent | 0.00% | 0.00%
NAPS | P/NAPS
-0.20 | 0.00
YoY
87.25%
NP Margin | ROE
-2.23% | 0.00%
F.Y. | Ann. Date
31-Dec-2023 | 29-Feb-2024
Annualized Result
Revenue | NP to SH
3,777,382.666 | 172,633.333
RPS | P/RPS
262.09 Cent | 0.14
EPS | P/E | EY
11.98 Cent | 2.96 | 33.74%
DPS | DY | Payout %
-
NAPS | P/NAPS
-
QoQ | YoY
203.47% | 389.45%
NP Margin | ROE
4.64% | 0.00%
F.Y. | Ann. Date
30-Sep-2024 | 26-Nov-2024
Business Process
| Trailing 4 Quarters | Trailing 8 Quarters | |||
|---|---|---|---|---|
| Available Quarters | 4 Quarters | 8 Quarters | ||
| Continuous Quarters Of Revenue Growth | 1 / 4 | 25.00% | 1 / 8 | 12.50% |
| Total Positive Profit Years | 3 / 4 | 75.00% | 5 / 8 | 62.50% |
| Continuous Quarters Of Positive Profit | 3 / 4 | 75.00% | 3 / 8 | 37.50% |
| Continuous Quarters Of Profit Growth | 1 / 4 | 25.00% | 1 / 8 | 12.50% |
| Continuous Quarters Of Adjusted EPS Growth | 1 / 4 | 25.00% | 1 / 8 | 12.50% |
| Total Dividend Years | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Continuous Quarters Of Dividend | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Continuous Quarters Of Dividend Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Continuous Quarters Of Adjusted Dps Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Average ROE | 0.00% | 0.00% | ||
| Average Net Profit Margin | 2.24% | -8.84% | ||
| Last 5 Financial Years | Last 10 Financial Years | |||
|---|---|---|---|---|
| Available Years | 5 Years | 10 Years | ||
| Continuous Quarters Of Revenue Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Total Positive Profit Years | 2 / 5 | 40.00% | 7 / 10 | 70.00% |
| Continuous Quarters Of Positive Profit | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Continuous Quarters Of Profit Growth | 1 / 5 | 20.00% | 1 / 10 | 10.00% |
| Continuous Quarters Of Adjusted EPS Growth | 1 / 5 | 20.00% | 1 / 10 | 10.00% |
| Total Dividend Years | 4 / 5 | 80.00% | 9 / 10 | 90.00% |
| Continuous Quarters Of Dividend | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Continuous Quarters Of Dividend Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Continuous Quarters Of Adjusted Dps Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Average ROE | 0.41% | 6.29% | ||
| Average Net Profit Margin | -4.04% | -0.57% | ||
Key Result
| T4Q | Annualized | Annual (Unaudited) | Last 10 FY Average | Last 5 FY Average | |
|---|---|---|---|---|---|
| Revenue | 3,622,844 | 3,777,382 | 3,404,481 | 2,848,595 | 3,455,154 |
| NP to SH | 96,754 | 172,633 | -77,452 | -31,457 | -126,869 |
| Dividend | 0 | 0 | 0 | 48,015 | 39,519 |
| Adjusted EPS | 6.71 | 11.98 | -5.37 | -2.18 | -8.80 |
| Adjusted DPS | 0.00 | 0.00 | 0.00 | 3.33 | 2.74 |
NP to SH = Net Profit Attributable to Shareholder, EPS = Earning Per Share, DPS = Dividend Per Share
All figures in '000 unless specified.
EPS & DPS's figures in Cent.
Growth
| LQ QoQ | LQ YoY | CQ YoY | LQ vs Average of T4Q | LQ vs Average of T8Q | |
|---|---|---|---|---|---|
| Revenue | 22.85% | 16.30% | 8.35% | 13.70% | 16.03% |
| NP to Owner | 3,512.16% | 304.77% | 389.45% | 317.69% | 236.45% |
| Dividend | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Adjusted EPS | 3,512.16% | 304.77% | 389.45% | 317.69% | 236.45% |
| Adjusted DPS | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LQ = Latest Quarter, CQ = Cumulative Quarter, T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, QoQ = Quarter on Quarter, YoY = Year on Year
| T4Q vs LFY | T4Q vs AL5FY | T4Q vs AL10FY | AQR vs LFY | AQR vs AL5FY | AQR vs AL10FY | LFY YoY | LFY vs AL5FY | LFY vs AL10FY | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.41% | 4.85% | 27.18% | 10.95% | 9.33% | 32.61% | -3.02% | -1.47% | 19.51% |
| NP to Owner | 224.92% | 176.26% | 407.57% | 322.89% | 236.07% | 648.79% | 87.25% | 38.95% | -146.21% |
| Dividend | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Adjusted EPS | 224.86% | 176.23% | 407.43% | 322.89% | 236.07% | 648.79% | 87.25% | 38.95% | -146.21% |
| Adjusted DPS | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, AL5FY = Average of Last 5 Financial Years, AL10FY = Average of Last 10 Financial Years, LFY = Latest Financial Year AQR = Annualized Quarter Result, YoY = Year on Year
Discussions
6 people like this. Showing 50 of 14,146 comments
got nothing to do with Biden drops from presidential race .. people over here still need pills and treatment. Pelaung to top up😅
2024-07-22 11:42
Is there a dateline set by BURSA for PN17 status to be removed? Anyone knows?
2024-08-01 08:16
Michael Kwok dari Kenanga ? 🤔
https://klse.i3investor.com/web/pricetarget/research/72061
2024-08-02 18:29
rare opportunity to grab at this level.. medical sector will not be affected by US burst.
2024-08-05 15:05
People still need treatments.. government continue with medical spending!. current price consider reasonable.. between 36 - 38 cents. In my opinion, medical sector will become safe heaven during this turmoil event
2024-08-05 15:15
OTHERS | https://www.klsescreener.com/v2/announcements/view/7963613
Omg resignation of auditors
2024-09-23 13:29
*** All look well.
*** Timely announcement: E&Y.
*** Improving biz trends.
*** Should be hot upon PN17 exit!
2 months ago
I think market are just waiting for uplift of PN17. Look at Dpharma, already up so much. Soon will be us.
2 months ago
bursa so lazy, its been mora than 6 month, not reply ..PMx should bur$4 activities which always favour the speculators!! so lazy la..
2 months ago
this company falls under strategic and security for the nation, asclong as no corrupt or mismanagmnt.. gahmen will always give support. Previous disaster due to previous govt request to stockile vaccine ..in the end, they dont buy. Ltat n bousted..may be replaced by khazanah or pnb, kwsp.
1 month ago
this QR sure outstanding from govt supply and indonesia business.. Pharma even sub-con Duopharma
3 weeks ago
why you should buy at current price.. starting this year.. this company can produce and supply INSULIN!!.. next year current Biocon-Duopharma contract expired, and gov will have option to split at least to this company.
3 weeks ago
Extremely good QR result~ next will be announcement plan to exit pn17.. more upsides coming
3 weeks ago
company value $500m, one QR already $100m !! ... some more out from pn7 soon. .. end of this week 50 cents. End of this year 60-70 cents!! .. obat list from 600 to 800 items. And vaccine+ Insuline. RM 1 company.
3 weeks ago
any one can feedback or commend about the regulation plan ? is it a good thing or bad thing for shareholder ?
3 weeks ago
now everybody will scramble to get a piece of this company.. regulation plan approved, profit improving, insulin will generate lots of profits, ..TP 1.0 year end !
1 week ago
For pharmaceutical players, innovations like Pharmaniaga Bhd’s (KL:PHARMA) locally produced recombinant insulin, which received National Pharmaceutical Regulatory Agency (NPRA) approval in November, is set to launch in the first quarter of 2025, which reflects the sector’s evolution towards meeting chronic disease demands.
https://theedgemalaysia.com/node/737010
1 week ago
post pandemic ramai sakit teruk, gula takda cukai betapa lama, kini ramai ada kencing manis, big demand for ubat lagipun, aging society in malaysia terlalu ramai orang tua, sakit, ubat up up up
1 week ago
msia jugak negara teramai si gemuk di asia... good biz for phrma ramai ada penyakit kronik ya... ubat demand up like crazy diba
1 week ago
Profitable
<%-- for fixing scrollbar--%>
Save Print Back
7081 PHARMA PHARMANIAGA BHD
Quarterly rpt on consolidated results for the financial period ended 30/09/2024
Quarter: 3rd Quarter
Financial Year End: 31/12/2024
Report Status: Unaudited
Submitted By:
Current Year Quarter Preceding Year Corresponding Quarter Current Year to Date Preceding Year Corresponding Period
30/09/2024 30/09/2023 30/09/2024 30/09/2023
RM '000 RM '000 RM '000 RM '000
1 Revenue 1,029,822 885,486 2,833,037 2,614,674
2 Profit/Loss Before Tax 138,485 (56,259) 180,863 (40,724)
3 Profit/(loss) attributable to ordinary equity holders of the parent 101,032 (49,339) 129,475 (44,731)
4 Net Profit/Loss For The Period 101,319 (49,047) 131,344 (43,957)
5 Basic Earnings/Loss Per Shares (sen) 7.01 (3.67) 8.98 (3.33)
6 Dividend Per Share (sen) 0.00 0.00 0.00 0.00
As At End of Current Quarter As At Preceding Financial Year End
7 Net Assets Per Share (RM) (0.1214) (0.2075)
Remarks:
You are advised to read the entire contents of the announcement or attachment.
To read the entire contents of the announcement or attachment, please access
the Bursa website at http://www.bursamalaysia.com
26/11/2024 07:00 AM
Ref Code: 202411263100074
3 days ago
Post a Comment
Featured Posts
Introducing MY's First IPO Fund for Sophisticated Investors!
New Update. Discover investment communities that resonate with your ideas
M & A Value Partners IPO Equity Fund has been launched - Targeted 13% Return p.a
Latest Videos
Apps
Top Articles
1
Stock Market Enthusiast
Top 3 AI/Data Center Newsflow for the 3rd Week of December - #TENAGA, #YTL, #YTLPOWER
2
Rakuten Trade Research Reports
3
save malaysia!
4
Good Articles to Share
5
Good Articles to Share
World’s largest stablecoin issuer Tether sees US$10b in net profits for 2024
6
Good Articles to Share
Honda and Nissan consider mutual production of vehicles, Kyodo reports
7
Good Articles to Share
8
Good Articles to Share
Economy won’t ‘radically change’ in 2025, strategist predicts
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
soon9913
Don't all in, get ready some money to subscribe the right issue
2024-07-21 15:12